Table 3 Adverse events and immunosuppression
From: Cell-therapy for Parkinson’s disease: a systematic review and meta-analysis
Study | Sample size | Adverse events | Immunosuppression | |||
|---|---|---|---|---|---|---|
Tumor | Immune rejection | GID | Others | |||
Schiess 2021 [102] | 20 | No | No | 4 patients (possibly related) | Phlebitis, hematoma, hypertension, nausea, headache, lymphocytosis | Not performed |
Venkataramana 2012 [103] | 8 | No | No | No | No | Not performed |
Boika 2020 [104] | 12 | NP | NP | NP | NP | Not performed |
Storch 2012 [105] | 7 | No | No | NP | NP | NP |
Brazzini 2010 [106] | 53 | No | No | No | No | Not performed |
Madrazo 2019 [107] | 7 | No | No | No | No | Cyclosporine A for 40 days |
Lige 2016 [108] | 21 | No | No | No | No | Not performed |
Sinelnyk 2015 [109] | 32 | No | No | No | No | Not performed |
Yin 2012 [110] | 12 | No | No | No | No | Not performed |
Gross 2011 [111] | 35 | No | No | 1 patient | Disturbance in attention, hallucination | Not performed |
Stover 2005 [112] | 6 | No | No | No | Hallucination | Not performed |